- Zacks•2 days ago
Monsanto Company (MON) recently secured a global non-exclusive license from The Broad Institute for usage the CRISPR-Cas genome-editing technology.
- Benzinga•3 days ago
HC Wainwright has started coverage of Oncomed Pharmaceuticals Inc (NASDAQ: OMED ) shares with a Buy rating. The firm sees 68 percent potential upside for the pharmaceutical company on upcoming opt-in decisions ...
Bayer AG (BAYRY)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||102.35 - 103.10|
|52wk Range||94.36 - 135.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||16.90|
|Avg Vol (3m)||84,826|
|Dividend & Yield||2.87 (2.79%)|